Author

J. S. O'Donnell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1 Organism:mouse· 1 Assay:protein structure· 1

Frequent Co-Authors

A. M. Curtis· 1 shared A. M. Rehill· 1 shared G. Leon· 1 shared I. Schoen· 1 shared J. A. Lackenby· 1 shared K. J. Chappell· 1 shared N. Jaberolansar· 1 shared N. Tardiota· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. M. Curtis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GLYCOLYTIC REPROGRAMMING FUELS MYELOID CELL-DRIVEN HYPERCOAGULABILITY

A. M. Rehill, G. Leon, S. McCluskey, I. Schoen, Y. Hernandez-Santana, S. L. Annett, P. Klavina, T. Robson, A. M. Curtis, T. Renne, S. Hussey, J. S. O'Donnell, P. T. Walsh, R. J. Preston

This study shows inflammation-induced glycolytic reprogramming in myeloid cells drives hypercoagulability and antifibrinolytic activity, with potential therapeutic implications.

Journal of Thrombosis and Haemostasis · Feb 1, 2024Peer-reviewedImmunology

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors

J. S. O'Donnell, N. Tardiota, N. Jaberolansar, J. A. Lackenby, K. J. Chappell

This study uses homology modeling to show that NRTIs bind HTLV-1 reverse transcriptase with similar affinity to HIV-1, supporting their potential use in HTLV-1 treatment.

bioRxiv · May 25, 2023Pharmacology & Toxicology